This analysis presents the survival of patients starting renal replacement therapy (RRT) in UK renal units ('centres'), and includes an analysis of survival by centre. Data from 59 of the 70 UK centres are included. This is the first year that UK centre anonymity has been removed from analysis of patient survival by centre. Survival after adjustment for comorbidity is also reported for the first time although this analysis is restricted to those centres returning data on comorbidity in at least 85% of incident patients. The importance of adjusting for comorbidity can be seen in that for one centre, after adjustment of survival for age and diagnosis, the adjusted 1 year after 90 day survival was 84.6%. After adjusting to the average comorbidity present across centres, survival increased to 90.4%. Improved comorbidity data returns by renal units may require investment in informatics staff and creating structural process at renal unit level for clinicians to support these data returns. From the date of first RRT, the 1 year survival of all patients (unadjusted for age) is 79%. From the 90th day of RRT (to allow comparison with other countries' 1 year survival), the 1 year survival is 83%. The age adjusted (60 years) survival for the 1 year after 90 day period is 86%. There is a high death rate in the first 90 days on RRT (6% of all patients starting RRT), a period not included in reports by many registries and other studies. The 5 year survival (including deaths within the first 90 days) rates are 58, 53, 44, 28, 19 and 12%, respectively for patients aged 18-34, 35-44, 45-54, 55-64, 65-74 and >75 years. The 'vintage effect' of increasing hazard of death with length of time on RRT, prominent in data from the US, is only noted in older age groups (65-75 and 75þ years) at 5-6 years after starting RRT. Six centres had a figure for the 1 year after 90 day survival which was outside 2 SDs from the mean for the UK: in three cases this was better survival, and in three, poorer survival, than expected. Poor reporting by renal units of patient comorbidity makes interpretation of these apparent differences in patient survival between centres difficult and a relationship to clinical performance cannot yet be inferred.
Introduction
The analyses presented in this chapter examine survival from the start of renal replacement therapy (RRT), they encompass the outcomes from the total incident UK dialysis population reported to the Registry since its inception, including the 21% who start on peritoneal dialysis (PD) and the 3% who receive a pre-emptive transplant and are not censored for transplantation. The results therefore show a true reflection of the whole UK RRT population. The incident survival figures reported here are better than those reported for the UK by the iDOPPS study [1] [which only includes a haemodialysis (HD) cohort]. Additionally, first year UK survival data includes patients who have died within the first 90 days of starting RRT, a period excluded from most other countries' registry data.
As shown in Chapters 3 and 6 [2, 3] , patients starting haemodialysis in the UK have higher levels of comorbidity and tend to be older than those starting RRT on PD or those pre-emptively transplanted.
The data set includes patients from England, Scotland and Wales. Northern Ireland has only recently joined the Registry and so there is not sufficient follow-up data available to enable survival analyses to be done. Patients returning to dialysis after a failed transplant are not included in this cohort.
Many of the survival figures quoted in this chapter are from the first day of RRT. In many instances survival from day 90 is also presented, as this allows comparison with many other registries, including the US, which record data only from day 90 onwards.
The distinction is important, as there is a high death rate in the first 90 days which would distort comparisons; in many other countries, patients are not reported to the national registry or considered to have established renal failure until they have completed 90 days on RRT, whereas in the UK all patients starting RRT are included from the date of the first RRT treatment unless they recover renal function within 90 days. The UK data, therefore, include patients who develop acute irreversible renal failure in the context of an acute illness, for instance.
To allow comparisons between centres with differing age distributions, survival analyses are statistically adjusted for age and reported as survival adjusted to 60 years. This age was chosen because it was approximately the average age of patients starting RRT 8 years ago at the start of the Registry's data collection. The average age of patients commencing RRT in the UK in 2005 is now closer to 65 years, but the Registry has maintained age adjustment to 60 years for comparability with previous years' analyses.
Survival rates in different centres contributing to the UK Renal Registry are reported here and this year, with the agreement of all UK clinical directors, centre anonymity has been removed. These are raw data that require very cautious interpretation if legitimate centre comparisons are to be attempted. The Registry can adjust for the effects of the different age distributions of the patients in different centres, but lacks sufficient data from many participating centres to enable adjustment for comorbidity and ethnic origin, which have been demonstrated to have a major impact on outcome. With this lack of information on case mix, it is difficult to interpret any apparent difference in survival between centres. Using data only from those centres with >85% complete data returns on comorbidity, an analysis has been undertaken to highlight the impact of changes in estimates of survival rates by centre after adjusting for age, primary renal diagnosis and comorbidity. It is hoped this will encourage all centres to allocate the resources to return the comorbidity data.
Despite the uncertainty about any apparent differences in outcome for centres which appear to be outliers, the Registry will follow the clinical governance procedures as set out in Chapter 2.
Statistical methodology
The take-on population in a year included patients who recover from established renal failure (ERF) after 90 days from the start of RRT, but excludes those that recover within 90 days. Patients newly transferred into a centre who were already on RRT were excluded from the take-on population for that centre. Patients restarting dialysis after a failed transplant were also excluded (unless they started RRT in that current year).
Patients who started treatment at a centre and then transferred out soon after starting RRT treatment were counted at the original centre.
For patients who recovered renal function for a period of time and then went back into ERF, the length of time on RRT was calculated from the day on which the patient re-started RRT. If recovery was for less than 90 days, the start of RRT was calculated from the date of the first episode and the recovery period ignored.
Patients who transferred out of their initial treatment centre were censored on the day they transferred out if there was no further information in the timeline.
The 1 year incident survival for patients in 2004 were for those who had all been followed for 1 full year through 2005. The 2005 incident patients were excluded from this year's incident survival analysis as they had not been followed for a sufficient length of time. Adjustment of 1 year after 90 day survival for comorbidity was undertaken using the combined incident cohort from 2000-2004. Twelve centres had returned >85% of comorbidity data for patients. Adjustment was first performed to a mean age of 60 years, then to the average primary diagnosis mix for all the 12 centres. The individual centre data were then further adjusted for average comorbidity mix present at these centres.
Survival of new patients on RRT

Comparison with Audit Standards
The 2002 UK Renal Standards document (www.renal. org) concluded that:
It is hard to set survival standards at present because these should be age, gender and comorbidity adjusted and this is not yet possible from Registry data. The last Standards document (1998) recommended at least 90% 1 year survival for patients aged 18-55 years with standard primary renal disease. This may have been too low as the rate in participating centres in the Registry was 97%, though numbers were small.
The Renal Standards document defines Standard
Primary Renal Disease using the EDTA-ERA diagnosis codes (including only codes 0-49), this excludes patients with renal disease due to diabetes and other systemic diseases. It is a more widespread practice to simply exclude patients with diabetes, so these figures are included in this report to allow comparison with reports from other registries. The results are shown in Table 12 .1 and are similar to the previous year.
Between country
Two years' incident data have been combined to increase the size of the patient cohort, so that any differences between the three UK countries are more likely to be identified (Table 12. 2). These data have not been adjusted for primary renal diagnosis, ethnicity or comorbidity.
Modality
The age-adjusted 1 year survival estimates on HD and PD are 85.3 and 90.2% respectively with the improvement in HD survival from 2002 to 2003 appearing to have been maintained. There appears to be better survival on PD compared with HD (Table 12. 3) after age adjustment, similar to data from the USRDS and Australasian (ANZDATA) Registries. However, a straightforward comparison of the modalities in this way is not valid, as there are significant factors in selection for the modalities and the patients in the two groups are not comparable [2, 3] . If the survival data in Tables 12.7-12.9 are calculated from day 90 (1 year after day 90 survival, 2 year after day 90 survival, etc.) the survival in all It should be noted that any 50% life expectancy estimates obtained from this graph will include diabetic patients. Also, if these estimates were to be compared with other countries, deaths in the first 3 months should be excluded and this would add approximately 6 months to the average life expectancy figures. It is also important to remember that the figure shows survival from the start of RRT and so cannot be used, for example, to estimate the life expectancy of a patient aged 50 who has been on dialysis for 10 years. When the monthly hazard of death (for the following month) is analysed by age (Figure 12. 3), a rapid fall in monthly hazard of death is seen in the first 3-4 months specifically in the older age groups. Table 12 .6 demonstrates that the age-related increase in hazard of death is different between the two time periods.
It should be noted that the data in Tables 12.7-12.9 are not adjusted for age. The median age of incident patients has increased over the period 1997-2004 and so an apparent decrease in patient survival could have been expected.
Change in survival on renal replacement therapy by vintage
Data from the USA [4] (USRDS Report 2006) has demonstrated a worsening prognosis on RRT with increase in years on dialysis (vintage) and this effect has not been demonstrated in previous analyses of UK data [6] .
Survival analysis of younger patients that have been censored at the time of transplantation, censors out those with better prognosis, leaving a biased subgroup of patients on dialysis. The analysis has therefore not been censored at transplantation.
The hazard of death was calculated for 6 monthly periods as the hazard at the mid-point within that time period. The first 3 month period has been excluded from this analysis. Analysis of patients in older age groups (65-75 and 75þ years) shows an increasing 6 monthly hazard of death at 5-6 years after starting RRT (Figure 12.4 ). This contrasts with data from the USA where this increasing hazard is seen beyond 2 years for all age groups. Previous Registry analyses have demonstrated that survival on RRT in the UK is better than in the USA [7] across all age ranges even though there are similar rates of comorbidity [8] . The reasons for this are unknown, but may also partly explain why there are also differences seen in the effect of vintage.
Analysis of the same data after excluding diabetic patients shows an even clearer trend (Figure 12.5) . Figure 12 .6 for diabetic patients shows no vintage effect and this may be related to the higher risk of death in this group of patients, overwhelming small changes from a vintage effect.
Time trend changes in incident patient survival, 1999-2004
Figure 12.7 shows the change over 5 years in incident patient survival. As the Registry does not currently cover the whole of the UK, any improvement in survival could be confounded by the effect of newer centres with lower mortality, reporting data for the first time. To allow for this, the left hand graph shows survival for the original 1999 Registry sites, which very closely follow the 'all sites' UK change in survival. This also indicates that the 1999 Registry data was very representative of the UK as a whole. All previous UK Registry reports have compared survival using the much smaller 1997 cohort.
Analysis of centre variability in 1 year after 90 days survival
The 1 year after 90 day survival for the 2004 incident cohort is shown in Figure 12 .8 for each renal unit. The tables for these data and for 90 day survival are in Appendix 1 at the end of this chapter (Tables 12.12 and 12.13).
In the analysis of 2004 survival data, some of the smaller centres have wide CIs (Figure 12.8) . This can be addressed by including a larger cohort, from all patients starting RRT 2001-2004, which also assesses sustained performance. A few centres have been contributing data to the Renal Registry for only part of this period so will have fewer years included. The survival results are shown for this larger cohort, using funnel plots to identify possible outliers (Figure 12.9) . From Figure 12 .9, for any size of incident cohort (X-axis) one can identify whether any given survival rate (Y-axis) falls within plus or minus 2 SDs from the national mean (solid lines, 95% CI) or 3 SDs (dotted lines, 99.8% CI). Table 12 .10 helps centres to identify themselves on this graph by finding their number of patients and then looking up this number on the X-axis. There are three centres that fall between 2-3 SDs below average (Plymouth, Glasgow Western and Edinburgh), one centre outside 3 SDs above average (Ipswich) and two other centres between 2 and 3 SDs above average (Sheffield and Hammersmith and Charing Cross). These data have not been adjusted for any patient-related factor except age (not comorbidity or primary renal disease or ethnicity) with both Plymouth and the Scottish centres returning no data on comorbidity. There is no censoring at transplantation, so the effect of differing unit rates of transplantation is not taken into account.
As discussed in an earlier report [8] , the general population of Scotland is known to have more ill health than England and Wales, reflected in 16% higher all-cause mortality [9] and particularly cardiovascular disease mortality [10, 11, 12] . Table 12 .11 subsequently shows differences in life expectancy between the UK countries [13] . Thus, a slightly higher dialysis mortality in Scotland may reflect the increased mortality in the population from which the dialysis patients are drawn. This emphasises the need to consider the characteristics of the general population from which patients come when considering or comparing outcomes of treatment.
Analysis of the impact of adjustment for comorbidity on the 1 year after 90 day survival (Figure 12 .10). The importance of adjusting for comorbidity can be seen for Swansea. After adjustment of survival for age and diagnosis, the 1 year after 90 day survival increased from 77-84.6%; after adjusting to the average comorbidity present in the 12 centres, survival increased to 90.4%. This indicates that patients starting RRT at the Swansea renal unit have more co-morbidities present than average for England & Wales. This contrasts with Wolverhampton where there is little change (85.5-85.6%). In both Dorset and Chelmsford, the adjusted survival falls indicating that patients at these centres have fewer comorbidities present.
This highlights the importance of improving comorbidity returns to the Renal Registry. 
